DCC0965 |
Bgt1-in-9 |
The first small-molecule substrate identified with high selectivity for BGT1 over the three other GAT subtypes; M1 muscarinic agonist |
|
DCC0966 |
Bh3i-2 |
Cell-permeable apoptosis inducer, specifically preventing BH3 domain-mediated interactions between pro-apoptotic and anti-apoptotic members of the Bcl-2 family |
|
DCC0967 |
Bhq-2-succinimide Ester |
Reactive dark quencher used in a variety of Fluorescence Resonance Energy Transfer (FRET) DNA detection probe. |
|
DCC0968 |
Bhq-o-5ht |
Novel photoactivatable form of serotonin |
|
DCC0969 |
Bi-0319 |
Novel PROTAC (proteolysis-targeting chimera) as a PTK2 protein degerader |
|
DCC0970 |
Bi-1750
Featured
|
BI-1750 is a highly selective and stable fluorogenic substrate designed for Cathepsin C (CatC), a lysosomal cysteine protease involved in various physiological and pathological processes. Its unique properties make it a powerful tool for studying CatC activity in both research and drug development contexts. |
|
DCC0971 |
Bi-1942 |
Novel potent inhibitor of human chymase with >100 fold selectivity against Cathepsin G |
|
DCC0972 |
Bi-2051 |
Novel highly selective, soluble and cellular permeable inhibitor of the P. falciparum protease dipeptidyl aminopeptidase 1 (DPAP1) |
|
DCC0973 |
Bi-3257 |
Novel inhibitor of HIV replication, preventing the formation of the capsid core structure that encapsulates the viral genome and its associated enzymes, reversing transcriptase and integrase |
|
DCC0974 |
Bi-4659 |
Novel potent and selective inhibitor of Alk5 (TGFßR1), blocking the phosphorylation of Smad2 and Smad3 in HaCaT cells |
|
DCC0975 |
Bi-5521 |
Novel potent and selective ATP-competitive inhibitor of glycogen synthase kinase (GSK-3), targeting both isoforms GSK-3α and GSK-3β |
|
DCC0976 |
Bi-7273 |
Novel highly potent dual inhibitor of BRD9/BRD7 |
|
DCC0977 |
Bi-730357 |
Novel RORγ antagonist for the treatment of autoimmune diseases |
|
DCC0978 |
bi-83c11 |
Non-ATP competitive inhibitor of JNK, targeting the JNK-JIP interaction |
|
DCC0979 |
Bi-9740 |
Novel potent, highly selective, and orally bioavailable CATHEPSIN C (CTSC, CatC) inhibitor |
|
DCC0980 |
Bibs-222 |
Novel nonpeptide angiotensin II receptor antagonist |
|
DCC0981 |
Bi-btk-1 |
Novel, highly selective and potent irreversible BTK inhibitor |
|
DCC0982 |
Bibx-1382 Dihydrochloride |
Potent, selective inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase |
|
DCC0983 |
Bicifadine |
Triple reuptake inhibitor (TRI) |
|
DCC0984 |
Biclofibrate |
Antilipidemic agent |
|
DCC0985 |
bicuculline Methobromide |
GABAA receptor antagonist |
|
DCC0986 |
Biemamide A |
Novel inhibitor of the TGF-β pathway, blocking the epithelial to mesenchymal transition |
|
DCC0987 |
Bifeprunox Mesylate |
Partial agonist at dopamine D2 and serotonin 1A receptors |
|
DCC0988 |
Biib028 |
Novel selective heat shock protein 90 inhibitor, prodrug of CF2772 |
|
DCC0989 |
Biib-057 |
Selective Syk inhibitor |
|
DCC0990 |
Biib068 Hemi-adipate |
Novel, Selective, Potent, Reversible Bruton's Tyrosine Kinase (BTK) Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases |
|
DCC0991 |
Biii-277cl |
Novel potent blocker of the NMDA receptor ion channel |
|
DCC0992 |
Biii-890cl |
Novel potent blocker of Nav1.2 sodium channels, protecting of brain tissue from ischemia |
|
DCC0993 |
Biliatresone |
Natural Biliary Toxin, causing extrahepatic biliary atresia |
|
DCC0994 |
bim5078 |
Potent HNF4α antagonist |
|